Ehealth: Second Life Impacts Diabetes Education & Self-Management

Type 2 Diabetes Clinical Trial

— SLIDES  

Official title:

Ehealth: Second Life Impacts Diabetes Education & Self-Management

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01186965
• Other study ID #: Pro00022132
• Secondary ID: R21LM010727-02
• Status: Completed
• Phase: N/A
• First received: August 19, 2010
• Last updated: March 4, 2015
• Start date: January 2011
• Est. completion date: August 2012

Study information

• Verified date: March 2015
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to to develop and evaluate the feasibility, usability, and effect of participation in SLIDES (a virtual diabetes community in Second Life) for providing interactive diabetes education, support, and resources.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 75 Years

Eligibility

Inclusion Criteria:

• current Duke Endocrinology patient

• are between 21 and 75 years old

• are able to speak and read English

• are computer literate (have used a computer for at least 6 months)

• understand how to use the Internet (have accessed the Internet on at least 6 occasions)

• have access to a computer with a non-dial-up Internet connection in a private location (home)

• are mentally capable of informed consent

• are reachable by telephone

• have no pre-existing medical condition(s) or severe diabetes related complications that would interfere with study participation (i.e., physical activity) or measures (e.g., renal failure, Stage III hypertension, severe orthopedic conditions or joint replacement scheduled within 6 months, paralysis, bleeding disorders, cancer, or receipt of pharmacologic doses of anti-coagulant medications [warfarin])

• are able to travel to Duke University Medical Center (DUMC) for follow-up appointments.

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Diabetes Mellitus
• Type 2 Diabetes

Intervention

Behavioral:
• eHealth program in the Virtual Environment (VE) platform Second Life
determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perceived Usefulness		3 and 6 months	No
Primary	Perceived Ease of Use		3 and 6 months	No
Primary	Process data		January 2011 through May 2012	No
Secondary	Demographics		baseline	No
Secondary	Metabolic Indicators		baseline, 3 months, 6 months	No
Secondary	Diabetes knowledge		baseline, 3 months, 6 months	No